Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a/EIF4E Axis
Authors:
Open Access
- 1 July 2020
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 5845-5855
Abstract
Purpose: The long-noncoding RNA MCM3AP-AS1 has been shown to participate in the tumorigenesis and growth of several types of cancer, but little is known about the role of MCM3AP-AS1 in the chemoresistance of lymphoma. Methods: A series of patients with Burkitt lymphoma were enrolled for clinical analysis. Daudi and Namalwa cells were used for further experiments. CCK-8 and apoptosis assays were used to assess the response to doxorubicin. Mitochondrial membrane potential assays and high-resolution respirometry were used to assess mitochondrial function. Western blotting was used to detect the expression of certain molecules. Luciferase assays and microRNA transfection were used to clarify the regulatory mechanisms of MCM3AP-AS1. An in vivo model using BALB/c nude mice was utilized to investigate the effects of MCM3AP-AS1 on cell proliferation and tumor growth. Results: The expression level of MCM3AP-AS1 was increased in tumors compared with normal lymph nodes, which indicated poor prognosis in patients with Burkitt lymphoma. Moreover, compared with siNC transfection, MCM3AP-AS1 knockdown decreased cell viability and increased apoptosis rates upon doxorubicin treatment compared with siNC. Further studies indicated that upregulation of several antiapoptotic factors, downstream of EIF4E, was partially responsible for MCM3AP-AS1-induced chemoresistance. Moreover, miR-15a functioned as a link between MCM3AP-AS1 and EIF4E, and was sponged by MCM3AP-AS1. Finally, we showed that the MCM3AP-AS1/miR-15a/EIF4E axis regulated the chemoresistance of lymphoma cells in vitro and in vivo. Conclusion: MCM3AP-AS1/miR-15a/EIF4E axis plays a role in the chemoresistance of Burkitt lymphoma, and it might become a promising target for lymphoma therapeutics.Keywords
This publication has 35 references indexed in Scilit:
- Pseudogene-Derived lncRNAs and Their miRNA Sponging Mechanism in Human CancerFrontiers in Cell and Developmental Biology, 2020
- Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?International Journal of Molecular Sciences, 2020
- LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195Life Sciences, 2019
- Modulation of cancer cell signaling by long noncoding RNAsJournal of Cellular Biochemistry, 2019
- Identification of novel lncRNAs regulated by the TAL1 complex in T-cell acute lymphoblastic leukemiaLeukemia, 2018
- Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphomaMolecular Cancer, 2017
- Long non-coding RNAs: potential new biomarkers for predicting tumor invasion and metastasisMolecular Cancer, 2016
- Long Noncoding RNA Expression Profiling in Normal B-Cell Subsets and Hodgkin Lymphoma Reveals Hodgkin and Reed-Sternberg Cell–Specific Long Noncoding RNAsThe American Journal of Pathology, 2016
- Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4GProceedings of the National Academy of Sciences, 2014
- FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphomaLeukemia, 2014